Related references
Note: Only part of the references are listed.The effect of metformin on biomarkers associated with breast cancer outcomes: a systematic review, meta-analysis, and dose-response of randomized clinical trials
J. Rahmani et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2020)
The C Allele of ATM rs11212617 Associates With Higher Pathological Complete Remission Rate in Breast Cancer Patients Treated With Neoadjuvant Metformin
Elisabet Cuyas et al.
FRONTIERS IN ONCOLOGY (2019)
Association of Metformin with Breast Cancer Incidence and Mortality in Patients with Type II Diabetes: A GRADE-Assessed Systematic Review and Meta-analysis
Grace H. Tang et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2018)
The Effects of Metformin and Weight Loss on Biomarkers Associated With Breast Cancer Outcomes
Ruth E. Patterson et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
The Effects of Metformin and Weight Loss on Biomarkers Associated With Breast Cancer Outcomes
Ruth E. Patterson et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Results of the safety run-in part of the METAL (METformin in Advanced Lung cancer) study: a multicentre, open-label phase I-II study of metformin with erlotinib in second-line therapy of patients with stage IV non-small-cell lung cancer
Floriana Morgillo et al.
ESMO OPEN (2017)
Measuring the biological effect of presurgical metformin treatment in endometrial cancer
V. N. Sivalingam et al.
BRITISH JOURNAL OF CANCER (2016)
Metformin in Cancer Treatment and Prevention
Daniel R. Morales et al.
ANNUAL REVIEW OF MEDICINE, VOL 66 (2015)
The association between glucose-lowering drug use and mortality among breast cancer patients with type 2 diabetes
Pauline A. J. Vissers et al.
BREAST CANCER RESEARCH AND TREATMENT (2015)
Evidence for biological effects of metformin in operable breast cancer: biomarker analysis in a pre-operative window of opportunity randomized trial
Sirwan M. Hadad et al.
BREAST CANCER RESEARCH AND TREATMENT (2015)
Current and emerging breast cancer biomarkers
Maryam Sana et al.
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS (2015)
Effect of Metformin vs Placebo on Weight and Metabolic Factors in NCIC CTG MA.32
Pamela J. Goodwin et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells
Carminia Maria Della Corte et al.
Oncotarget (2015)
Effect of Metformin vs Placebo on Weight and Metabolic Factors in NCIC CTG MA.32
Pamela J. Goodwin et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Metformin and metabolic diseases: a focus on hepatic aspects
Juan Zheng et al.
FRONTIERS OF MEDICINE (2015)
Antiproliferative and metabolic effects of metformin in a preoperative window clinical trial for endometrial cancer
Kevin M. Schuler et al.
CANCER MEDICINE (2015)
Effects of Metformin on Endometrial Cancer Cell Growth in Vivo: A Preoperative Prospective Trial
Akira Mitsuhashi et al.
CANCER (2014)
Presurgical Trial of Metformin in Overweight and Obese Patients with Newly Diagnosed Breast Cancer
Kevin Kalinsky et al.
CANCER INVESTIGATION (2014)
Anti-diabetic doses of metformin decrease proliferation markers in tumors of patients with endometrial cancer
Ido Laskov et al.
GYNECOLOGIC ONCOLOGY (2014)
Metformin-mode of action and clinical implications for diabetes and cancer
Ida Pernicova et al.
NATURE REVIEWS ENDOCRINOLOGY (2014)
A pilot 'window of opportunity' neoadjuvant study of metformin in localised prostate cancer
A. M. Joshua et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2014)
Correlation of TNFAIP8 overexpression with the proliferation, metastasis, and disease-free survival in endometrial cancer
Tianbo Liu et al.
TUMOR BIOLOGY (2014)
The effect of metformin on apoptosis in a breast cancer presurgical trial
M. Cazzaniga et al.
BRITISH JOURNAL OF CANCER (2013)
Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP
Russell A. Miller et al.
NATURE (2013)
Metformin Downregulates the Insulin/IGF-I Signaling Pathway and Inhibits Different Uterine Serous Carcinoma (USC) Cells Proliferation and Migration in p53-Dependent or -Independent Manners
Rive Sarfstein et al.
PLOS ONE (2013)
Dual Effect of Metformin on Breast Cancer Proliferation in a Randomized Presurgical Trial
Bernardo Bonanni et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial
Sirwan Hadad et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Metformin is a potent inhibitor of endometrial cancer cell proliferation-implications for a novel treatment strategy
Leigh A. Cantrell et al.
GYNECOLOGIC ONCOLOGY (2010)
Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer
Mitch Dowsett et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells
Mahvash Zakikhani et al.
CANCER RESEARCH (2006)
Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer
Russell Burcombe et al.
BREAST CANCER RESEARCH (2006)
Prognostic impact of alterations in P-cadherin expression and related cell adhesion markers in endometrial cancer
IM Stefansson et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Share Paper
